CPRI’s high-quality small-scale services complement Lonza’s extensive capabilities in custom cGMP peptide manufacturing and development.
With proximity to a core customer base in the North American pharmaceutical market, CPRI adds geographic diversity to Lonza’s existing facilities in Braine-l’Alleud (Belgium), Visp (Switzerland), Nansha (China) and Kou?im (Czech Republic). CPRI’s offering includes milligram- to multi-gram-scale custom synthesis and a wide variety of catalogue products, as well as consulting services and technical support.
The alliance will provide customers a more complete peptide offering – from research through commercial supply – and enable a seamless transition of custom peptide projects between CPRI’s small-scale facility and Lonza’s cGMP facilities.
Source: Lonza
© FoodBev Media Ltd 2024